The ASN 2017 Kidney Week Congress starts this week in New Orleans. In this article, the COMPACT RENAL team has highlighted key sessions and posters relating to CKD-MBD.
Note that hyperlinks to symposia will take you to the ASN Kidney Week website, where you will have the option to add sessions to your calendar. Links in  point to abstracts.
Thursday 02 November
An industry symposium at 12:45pm at the Hilton Riverside, Grand Salon 1, will focus on achieving optimal mineral metabolism in hemodialysis patients with hyperparathyroidism. The session, moderated by Tamara Isakova, will also focus on goals of therapy and new approaches.
At 2pm, a clinical practice session entitled Revisiting Parathyroidectomy in ESRD will include a presentation by Kamyar Kalantar-Zadeh, USA (a member of the COMPACT Renal Faculty Board), discussing trends in parathyroid hormone control and parathyroidectomy use in ESRD.
At 4:30pm, Michel Jadoul, Belgium will present the recently-published KDIGO 2017 CKD-MBD guidelines in an oral symposium. Also at 4.30pm, an oral abstract session will include a presentation on ferric citrate’s effects on FGF23 in patients with non-dialysis dependent chronic kidney disease and iron deficiency anaemia [TH-OR038].
Posters on Thursday will include:
- Five posters, which demonstrate the effectiveness of the phosphate binder sucroferric oxyhydroxide, based on data from real-world studies [TH-PO785, TH-PO1030, TH-PO1031, TH-PO1032, TH-PO1033]
- Two posters presenting sub-analyses of clinical trial data for the prohormone vitamin D therapy, extended-release calcifediol [TH-PO513, TH-PO515]
- Several posters presenting data on pipeline hyperphosphatemia therapies, including two on tenapanor, a NHE3 inhibitor, discussing its GI side-effects [TH-PO1045] and efficacy [TH-PO1046]
Friday 03 November
In the Hilton Riverside, Grand Ballroom A, at 12.45, an industry symposium will focus on phosphorus management in CKD. Sadiq Ahmed, USA will moderate, with Sagar Nigwekar, USA presenting on the causes and consequences of hyperphosphatemia, while Rasheed Balogun, USA will discuss optimal management via a realistic diet and potent phosphate binder use.
An oral abstract session symposia at 16:30 will include a presentation discussing five identified FGF23 trajectories among patients undergoing chronic hemodialysis in the HEMO Study [FR-OR077]
In the poster hall, presentations will include:
- An interim analysis of the prospective VERIFIE study showed that sucroferric oxyhydroxide was well tolerated and effective at reducing serum phosphate [FR-PO886]
- A poster on calcitriol treatment groups which exhibited similar increases in FGF-23, vascular calcification, and endothelial dysfunction independent of dosing regimen in rats [FR-PO288]
- Late-breaking posters, with details still to be released at the time of writing
Saturday 04 November
On Saturday two oral symposia feature on the CKD-MBD congress stream:
- At 2pm, Bone: Victim or Culprit in CKD includes presentations on the pathophysiology of CKD-MBD, including one on longitudinal studies of mineral metabolism in CKD
- At 4:30pm, an oral abstracts session on mineral disease will also focus on the pathophysiology of the disease [SA-OR021, SA-OR022], as well as the effects of dietary phosphate on blood pressure in healthy adults [SA-OR027]
Posters on Saturday include an investigator initiated study which suggests that 25(OH)D ameliorates phosphate-induced calcification via inhibition of PiT2 expression in human VSMCs [SA-PO855].
Sunday 05 November
Sunday morning sessions are expected to be quiet in the CKD-MBD stream.
We wish you a safe journey to New Orleans and we look forward to reporting back from the congress on the key presentations.